BRIDGEWATER, N.J. – Patients with diabetes who switch from insulin pens or syringes to the V-Go Wearable Insulin Delivery device experienced a greater reduction in A1C levels and insulin total daily dose, according to the results of a recent study published by Valeritas Holdings, providers of the V-Go device. “We believe V-Go provides patients a simple and convenient way to deliver basal-bolus insulin and the findings from this new study continues to support the use of V-Go for insulin delivery results in better glucose control,” said John Timberlake, president and CEO of Valeritas Holdings, in a statement. The V-Go device is worn like a patch and can eliminate the need for taking multiple daily shots. The ENABLE (Effectiveness of V-Go Wearable Insulin Delivery for Basal-Bolus Therapy) study—a real-world, retrospective, multi-center analysis evaluating the achievement of blood glucose targets in 283 patients with Type 2 diabetes—found that after seven months of V-Go use, there were significant reductions in A1C and TDD.
You are here: / / V-Go wearable lowers A1C better than pens or syringes, study finds